藥物不良反應(yīng)該由誰(shuí)報(bào)告？
我國(guó)《藥品不良反應(yīng)監(jiān)測(cè)管理辦法》（試行）（以下簡(jiǎn)稱《辦法》）規(guī)定藥品生產(chǎn)經(jīng)營(yíng)企業(yè)和醫(yī)療預(yù)防保健機(jī)構(gòu)按規(guī)定報(bào)告所發(fā)現(xiàn)的藥品不良反應(yīng)。
《辦法》明確規(guī)定了報(bào)告的單位，但未明確報(bào)告人。由于ADR報(bào)告的質(zhì)量和報(bào)告人的藥物知識(shí)和臨床經(jīng)驗(yàn)有關(guān)，因此，報(bào)告人通常為醫(yī)師、藥師，以及護(hù)師等衛(wèi)生技術(shù)人員。至于患者是否可以報(bào)告ADR，各國(guó)規(guī)定不盡相同。
按《辦法》第二十條規(guī)定，個(gè)人發(fā)現(xiàn)藥品引起的ADR可以報(bào)告。但英國(guó)ADR監(jiān)測(cè)機(jī)構(gòu)考，試大網(wǎng)站收集不直接收患者的ADR報(bào)告，而建議患者通過醫(yī)師、藥師填寫黃卡上報(bào)，并對(duì)此作出說明如下：
we do not accept reports directly from patients ， as we consider that medical interpretation of the suspected reaction is vital. We advise patients who suspect they have had an adverse reaction to their medicine to discuss this with their doctor or pharmacist. The doctor or pharmacist may then report this via the yellow card scheme， if they consider it to be appropriate.
我國(guó)《藥品不良反應(yīng)監(jiān)測(cè)管理辦法》（試行）（以下簡(jiǎn)稱《辦法》）規(guī)定藥品生產(chǎn)經(jīng)營(yíng)企業(yè)和醫(yī)療預(yù)防保健機(jī)構(gòu)按規(guī)定報(bào)告所發(fā)現(xiàn)的藥品不良反應(yīng)。
《辦法》明確規(guī)定了報(bào)告的單位，但未明確報(bào)告人。由于ADR報(bào)告的質(zhì)量和報(bào)告人的藥物知識(shí)和臨床經(jīng)驗(yàn)有關(guān)，因此，報(bào)告人通常為醫(yī)師、藥師，以及護(hù)師等衛(wèi)生技術(shù)人員。至于患者是否可以報(bào)告ADR，各國(guó)規(guī)定不盡相同。
按《辦法》第二十條規(guī)定，個(gè)人發(fā)現(xiàn)藥品引起的ADR可以報(bào)告。但英國(guó)ADR監(jiān)測(cè)機(jī)構(gòu)考，試大網(wǎng)站收集不直接收患者的ADR報(bào)告，而建議患者通過醫(yī)師、藥師填寫黃卡上報(bào)，并對(duì)此作出說明如下：
we do not accept reports directly from patients ， as we consider that medical interpretation of the suspected reaction is vital. We advise patients who suspect they have had an adverse reaction to their medicine to discuss this with their doctor or pharmacist. The doctor or pharmacist may then report this via the yellow card scheme， if they consider it to be appropriate.